Selected pathological features of PBL (literature review from 1997 to 2014)
| Feature . | All cases . | HIV-positive . | HIV-negative . | Posttransplant . |
|---|---|---|---|---|
| Immunophenotype | ||||
| CD10 | 20% | 32% | 15% | 0% |
| CD20 | Low | 8% | 3% | 3% |
| CD30 | Subset | |||
| CD45 | Low | 31% | 33% | 70% |
| CD56 | 25% | 27% | 22% | 42% |
| CD79a | Common | 45% | 36% | 68% |
| CD138 | 90% | 94% | 87% | 88% |
| ALK-1 | 0% | |||
| BCL-2 | Uncommon | |||
| BCL-6 | Negative | |||
| EMA | Common | |||
| HHV-8 | 0% | 0% | 0% | 0% |
| IRF-4/MUM-1 | ∼100% | ∼100% | ∼100% | 100% |
| EBV LMP-1 | Uncommon | Occasional | Occasional | |
| EBNA-2 | Negative | |||
| EBV latency pattern | Type I | Type I or III | Type I | Type III |
| Cytoplasm Ig | Common | |||
| MIB-1/Ki-67 | High | 90% | 83% | 88% |
| PAX-5 | Negative | |||
| MYC | ∼50% | |||
| TP53 | ∼50% | 67% | 8% | |
| Molecular testing | ||||
| BCL-2 GR | Negative | |||
| BCL-6 GR | Negative | |||
| EBER | 66% | 75% | 50% | 67% |
| IgH GR | Monoclonal | |||
| MYC GR/amplifications | 57% | 78% | 44% | 38% |
| TCR GR | Polyclonal | |||
| Gene profile | Segmental gains: 1p35.1-1p36.12, 1q21.1-1q23.1, 1p36.11-1p36.33 | DNMT3B, PTP4A3, CD320 |
| Feature . | All cases . | HIV-positive . | HIV-negative . | Posttransplant . |
|---|---|---|---|---|
| Immunophenotype | ||||
| CD10 | 20% | 32% | 15% | 0% |
| CD20 | Low | 8% | 3% | 3% |
| CD30 | Subset | |||
| CD45 | Low | 31% | 33% | 70% |
| CD56 | 25% | 27% | 22% | 42% |
| CD79a | Common | 45% | 36% | 68% |
| CD138 | 90% | 94% | 87% | 88% |
| ALK-1 | 0% | |||
| BCL-2 | Uncommon | |||
| BCL-6 | Negative | |||
| EMA | Common | |||
| HHV-8 | 0% | 0% | 0% | 0% |
| IRF-4/MUM-1 | ∼100% | ∼100% | ∼100% | 100% |
| EBV LMP-1 | Uncommon | Occasional | Occasional | |
| EBNA-2 | Negative | |||
| EBV latency pattern | Type I | Type I or III | Type I | Type III |
| Cytoplasm Ig | Common | |||
| MIB-1/Ki-67 | High | 90% | 83% | 88% |
| PAX-5 | Negative | |||
| MYC | ∼50% | |||
| TP53 | ∼50% | 67% | 8% | |
| Molecular testing | ||||
| BCL-2 GR | Negative | |||
| BCL-6 GR | Negative | |||
| EBER | 66% | 75% | 50% | 67% |
| IgH GR | Monoclonal | |||
| MYC GR/amplifications | 57% | 78% | 44% | 38% |
| TCR GR | Polyclonal | |||
| Gene profile | Segmental gains: 1p35.1-1p36.12, 1q21.1-1q23.1, 1p36.11-1p36.33 | DNMT3B, PTP4A3, CD320 |
ALK-1, anaplastic lymphoma kinase 1; EBNA-2, EBV nuclear antigen 2; EMA, epithelial membrane antigen; GR, gene rearrangement; IRF-4/MUM-1, interferon regulatory factor 4/multiple myeloma 1; LMP-1, latent membrane protein 1; TCR, T-cell receptor.